Prof Heather Payne (University College Hospital, London, UK), Prof Alicia Morgans (Dana-Farber Cancer Institute, Boston, USA) and Prof Bertrand Tombal (Université catholique de Louvain, Brussels, Belgium) discuss quality of life and safety in novel therapies for prostate cancer. Initially, they discuss the definition of HRQoL and the lessons learnt in the last 10 years about QoL and safety in novel therapies for prostate cancer.
Prof Payne and Prof Tombal then discuss how QoL is measured and what it means for the patients. They talk about the health-related quality of life (HRQoL) in the GALAHAD study, ACIS trial and the ARAMIS Trial. They further discuss the impact of docetaxel on Quality of Life (QoL) in elderly and non-Elderly metastatic castration-resistant prostate cancer (mCRPC) patients and depression and anxiety in prostate cancer patients.
Prof Payne mentions safety of tazemetostat in combination with abiraterone/prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer. Prof Morgans talks about the considerations for men with co-morbidities and the impact of polypharmacy. Prof Payne concludes by discussing the future for prostate cancer patients with regards to the current data available.
|Definition of QoL|
|Learnings from the last 10 years regarding QoL|
|Depression and anxiety in prostate cancer patients|
|QoL in elderly and non-elderly mCRPC patients>|
|Safety of tazemetostat in combination with abiraterone/prednisone or enzalutamide|
This programme has been supported by an unrestricted educational grant from Janssen.